GERN

Geron Corp

0.9898

Nov 06 • 3:59 PM ET +0.0397 (4.18%)

1.00

Aftermarket • 7:53 PM ET +0.01 (1.03%)

Healthcare Biotechnology USA Small NASD

Peers: AGIO DMRA RIGL INCY BMY KROS SNDX IRON AAPG GLUE

| Held by: VTI XBI IWM VXF IWO IBB VTWO SCHA VHT BBP

Scroll to Statements

Index	RUT
Market Cap	637.67M
Enterprise Value	599.57M
Income	-50.12M
Sales	217.52M
Book/sh	0.35
Cash/sh	0.45
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	258
IPO	Jul 31, 1996

P/E	-
Forward P/E	12.37
PEG	-
P/S	2.93
P/B	2.81
P/C	2.21
P/FCF	-
EV/EBITDA	-
EV/Sales	2.76
Quick Ratio	4.61
Current Ratio	6.31
Debt/Eq	1.10
LT Debt/Eq	1.00
Option/Short	Yes / Yes

EPS (ttm)	-0.07
EPS next Y	0.08
EPS next Q	0.01
EPS this Y	83.08%
EPS next Y	463.64%
EPS next 5Y	-
EPS past 3/5Y	30.48% 14.78%
Sales past 3/5Y	575.71% 273.49%
EPS Y/Y TTM	37.60%
Sales Y/Y TTM	18.60%
EPS Q/Q	107.25%
Sales Q/Q	27.45%
Earnings	Nov 04 BMO
EPS/Sales Surpr.	100.00% -0.28%

Insider Own	1.43%
Insider Trans	0.00%
Inst Own	73.71%
Inst Trans	-1.60%
ROA	-9.16%
ROE	-21.08%
ROIC	-11.07%
Gross Margin	94.50%
Oper. Margin	-8.25%
Profit Margin	-23.04%
SMA20	-9.39%
SMA50	-19.90%
SMA200	-30.12%
Trades

Shs Outstand	644.24M
Shs Float	635.02M
Short Float	11.75%
Short Ratio	6.14
Short Interest	74.61M
52W High	2.01 -50.76%
52W Low	0.84 17.83%
Volatility	9.55% 7.46%
ATR (14)	0.08
RSI (14)	40.65
Beta	0.58
Rel Volume	1.12
Avg Volume	12.15M
Volume	13,652,188

Perf Week	10.67%
Perf Month	-18.87%
Perf Quarter	-33.12%
Perf Half Y	-28.79%
Perf YTD	-25.02%
Perf Year	-8.35%
Perf 3Y	-46.50%
Perf 5Y	-40.01%
Perf 10Y	-47.91%
Recom	1.40
Target Price	3.50
Prev Close	0.95
Price	0.99
Change %	4.18%

Consensus

Strong Buy

Avg. Price Target

$3.50

Implied Upside

+253.6%

Analysts12incl. previous ratings

Rating Distribution7 Buy · 4 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jul 10, 2025	Resumed	GGoldman	Sell	$1	+1.0%
May 08, 2025	Downgrade	BScotiabank	Sector Outperform → Sector Perform	$1.50	+51.5%
Feb 27, 2025	Downgrade	RB. Riley Securities	Buy → Neutral	$3.50 → $2	+102.1%
Feb 26, 2025	Downgrade	HH.C. Wainwright	Buy → Neutral
Nov 05, 2024	Initiated	HH.C. Wainwright	Buy	$8	+708.2%
Oct 16, 2024	Initiated	BScotiabank	Sector Outperform
Sep 09, 2024	Initiated	LLeerink Partners	Outperform	$7	+607.2%
Apr 30, 2024	Downgrade	RRobert W. Baird	Outperform → Neutral	$4.50	+354.6%
Apr 29, 2024	Initiated	TTD Cowen	Buy	$10	+910.3%
Mar 15, 2024	Reiterated	NNeedham	Buy	$4 → $5	+405.2%
Sep 12, 2023	Upgrade	GGoldman	Neutral → Buy	$4	+304.1%
Mar 28, 2023	Initiated	GGoldman	Neutral	$3	+203.1%
Oct 28, 2022	Initiated	WWedbush	Outperform	$5	+405.2%
Jul 28, 2022	Resumed	RB. Riley Securities	Buy	$4	+304.1%
Nov 02, 2021	Initiated	RRobert W. Baird	Outperform	$4	+304.1%
Feb 18, 2021	Resumed	RB. Riley Securities	Buy	$4	+304.1%
Aug 03, 2020	Initiated	SStifel	Buy	$3	+203.1%
Nov 19, 2019	Resumed	BB. Riley FBR	Buy	$4	+304.1%
Sep 03, 2019	Initiated	HH.C. Wainwright	Buy	$4	+304.1%
Aug 15, 2019	Initiated	CCantor Fitzgerald	Overweight	$4	+304.1%

Nov-04-26 09:26AM	Geron Turns Profitable As RYTELO Demand Accelerates, But The Myelofibrosis Failure Leaves A One-Product Story (Earnings Whispers) +16.13%
09:00AM	Geron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO (imetelstat) at ASH 2026 (GlobeNewswire)
07:03AM	Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-03-26 08:00AM	Geron Corporation to Participate in the Stifel 2026 Healthcare Conference (GlobeNewswire)
Oct-30-26 08:11AM	Geron winds down Phase III rare blood cancer trial after muted efficacy (Clinical Trials Arena) -5.47%
08:56AM	Loading…
Oct-28-26 08:56AM	Geron stock tumbles after halting Phase 3 trial (Investing.com) -15.78%
08:00AM	Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis (GlobeNewswire)
Oct-27-26 01:16PM	Geron's Rytelo Ramp Faces A Math Test As Stock Slides Toward Its Lows (Earnings Whispers)
Oct-21-26 08:00AM	Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026 (GlobeNewswire) -6.45%
Oct-19-26 04:01PM	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-13-26 02:52PM	Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire)
Oct-12-26 08:03AM	Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia (GlobeNewswire)
Sep-25-26 10:35PM	Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire)
Sep-18-26 04:01PM	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-02-26 03:58PM	Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire) +7.43%
08:00AM	Loading…
08:00AM	Geron to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-18-26 04:01PM	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-05-26 03:04PM	Geron Corp (GERN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) +21.64%
07:33AM	Geron: Q2 Earnings Snapshot (Associated Press)
07:00AM	Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-22-26 04:01PM	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026 (GlobeNewswire)
Jul-14-26 04:26PM	Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-13-26 08:00AM	Geron Announces Appointment of Chinmaya Rath as Chief Business Officer (GlobeNewswire) -5.33%
Jun-18-26 04:01PM	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.35%
Jun-01-26 08:00AM	Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire)
May-20-26 04:48PM	Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Quartz)
09:50AM	Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets (PR Newswire)
May-18-26 04:01PM	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-12-26 09:31AM	First Real-World Evidence Study of RYTELO (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026 (GlobeNewswire)
07:26AM	Loading…
May-06-26 07:26AM	Geron: Q1 Earnings Snapshot (Associated Press)
07:00AM	Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
May-05-26 08:00AM	Geron Plans to Present at Upcoming Investor Conferences (GlobeNewswire) +5.10%
Apr-22-26 07:00AM	Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026 (GlobeNewswire)
Apr-20-26 04:05PM	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.14%
Apr-14-26 04:05PM	Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-13-26 08:00AM	Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary (GlobeNewswire)
Apr-06-26 08:00AM	Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire) +5.42%
Mar-26-26 08:00AM	Geron Announces Appointment of New Members to its Board of Directors (GlobeNewswire)
Mar-18-26 04:05PM	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-05-26 12:53PM	Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline? (Zacks)
Mar-03-26 09:00AM	Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone (PR Newswire) -7.10%
Feb-26-26 02:27PM	Geron (GERN) 2025 Revenue Surges to $183.6M Driven by RYTELO Commercial Success (Insider Monkey)
Feb-25-26 02:02PM	Geron Corp (GERN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments (GuruFocus.com) -11.79%
12:15PM	Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
11:03AM	Geron Q4 Earnings Call Highlights (MarketBeat)
07:28AM	Geron: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-23-26 09:58AM	Geron (GERN) Sets 2026 Financial Goals, TD Cowen Cuts PT (Insider Monkey) -5.85%
08:00AM	Geron Plans to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-19-26 08:10AM	Insmed (INSM) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
Feb-18-26 04:15PM	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.78%
Feb-11-26 07:27AM	Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 (GlobeNewswire)
Jan-30-26 02:58PM	TD Cowen Maintains Buy Rating for Geron (GERN) While Trimming PT to $3 Ahead of Q4 Results (Insider Monkey)
Jan-18-26 12:29PM	Geron Corporation (GERN) Eyes Profitability in 2026 amid Restructuring Drive (Insider Monkey)
Jan-14-26 02:13PM	Geron Corporation (GERN) Streamlines Operations, Secures Financing, Eyes 2026 Growth (Insider Monkey)
Jan-12-26 08:00AM	Geron Corporation Provides 2026 Financial Guidance (GlobeNewswire) +6.72%
Jan-07-26 04:45AM	Geron (GERN) Plans Restructuring to Cut Costs, H.C. Wainwright Stays Neutral (Insider Monkey)
Dec-18-25 04:30PM	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01:14AM	Geron Corporation (GERN) Restructuring to Lower Operating Expenses as it Eyes Profitability in 2026 (Insider Monkey)
Dec-12-25 05:18AM	Praxis tees up another approval filing; Geron turns to layoffs (BioPharma Dive)
Dec-11-25 11:40PM	Geron Corporation (GERN) Presents New Data at the 67th American Society of Hematology 2025 Annual Meeting (Insider Monkey) +8.59%
08:00AM	Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation (GlobeNewswire)
Dec-08-25 08:02AM	Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO (Imetelstat) in Lower-Risk MDS (GlobeNewswire)
Dec-04-25 12:20PM	Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points (PR Newswire)
Nov-24-25 09:47AM	Wall Street Turns Bullish on Geron Corporation (GERN) amid Rytelo Sales Push Plans (Insider Monkey)
Nov-05-25 04:04PM	Geron Corp (GERN) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst RYTELO Demand Challenges (GuruFocus.com) -5.22%
08:25AM	Geron (GERN) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:19AM	Geron: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights (Business Wire)
Nov-04-25 08:00AM	Geron Corporation to Present at Upcoming Investor Conferences (Business Wire)
Nov-03-25 09:05AM	Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO (imetelstat) in Myeloid Hematologic Malignancies (Business Wire)
Oct-30-25 10:00AM	Arcellx, Inc. (ACLX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-29-25 10:00AM	Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-27-25 08:00AM	Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025 (Business Wire)
Oct-20-25 05:32PM	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.83%
Oct-13-25 04:34PM	Geron Corporation Announces Executive Leadership Transitions and Appointments (GlobeNewswire)
Sep-18-25 04:01PM	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
10:03AM	CG Oncology, Inc. (CGON) Moves 5.5% Higher: Will This Strength Last? (Zacks)
Aug-31-25 12:16AM	What Do Investors Think About Geron Corporation (GERN) Following Q2 Results? (Insider Monkey)
Aug-27-25 04:05PM	Geron to Participate in the 2025 Wells Fargo Healthcare Conference (Business Wire)
Aug-24-25 12:53AM	Needham Keeps Buy Rating on Geron (GERN) After Q2 Results (Insider Monkey)
Aug-22-25 11:45PM	Leerink Partners Reiterates a Buy on Geron Corporation (GERN), Keeps the PT (Insider Monkey)
Aug-19-25 12:08AM	Geron Corporation (GERN) Announces Grant of Stock Options; Scotiabank Reiterates 'Hold' Rating (Insider Monkey)
Aug-18-25 04:01PM	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-17-25 11:41PM	Geron Corporation Names Harout Semerjian as New CEO to Lead Commercialization of RYTELO (Insider Monkey)
Aug-08-25 04:01PM	Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.25%
Aug-07-25 03:07AM	Geron Corp (GERN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements (GuruFocus.com) -6.47%
Aug-06-25 08:15AM	Geron (GERN) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +15.83%
07:13AM	Geron: Q2 Earnings Snapshot (Associated Press Finance)
07:01AM	Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights (Business Wire)
07:00AM	Geron Appoints Harout Semerjian as President and Chief Executive Officer (Business Wire)
Jul-29-25 08:20AM	Incyte (INCY) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
Jul-28-25 08:00AM	Geron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025 (Business Wire) -8.73%
Jul-18-25 04:05PM	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-15-25 08:58AM	Geron Presents Positive RYTELO Data for LR-MDS at ASCO & EHA, Highlights Efficacy, Myelofibrosis Program Progress (Insider Monkey) -5.97%
Jul-07-25 09:10AM	Leerink Partners Reiterates a Buy Rating on Geron Corporation (GERN) (Insider Monkey)
Jun-18-25 04:10PM	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.90%
May-28-25 08:30AM	Geron Announces Presentations at ASCO and EHA Underscoring RYTELO (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROBERTSON MICHELLE	EVP, CHIEF FINANCIAL OFFICER	Feb 18 '26	Option Exercise	0.00	27,500	0	27,500	Feb 19 06:10 PM
ROBERTSON MICHELLE	EVP, CHIEF FINANCIAL OFFICER	Feb 18 '26	Sale	1.94	9,855	19,119	17,645	Feb 19 06:10 PM
JAMES ZIEGLER	Officer	Dec 15 '25	Proposed Sale	1.37	20,000	27,400		Dec 15 05:33 PM

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

CEOMr. Harout Semerjian

EVPMs. Michelle J. Robertson

Executive VP of Research & Development and Chief Medical OfficerDr. Joseph Emile Eid M.D.

Executive VP & Chief Commercial OfficerMr. Ahmed ElNawawi

Senior VP & Chief Technical OfficerMr. Shanthakumar Tyavanagimatt

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GERN

Geron Corp

Upgrade your Finviz experience